Document:

Exhibit 10.1

 

GOVERNMENT PROPERTIES INCOME TRUST

 

Summary of Trustee Compensation

 

The following is a summary of the currently effective compensation of the Trustees of Government Properties Income Trust (the “Company”) for services as Trustees, which is subject to modification at any time by the Board of Trustees (the “Board”) or the Compensation Committee of the Board, as applicable.

 

·                  Each Independent Trustee receives an annual fee of $40,000 for services as a Trustee, plus a fee of $1,250 for each meeting attended. Up to two $1,250 fees are paid if a Board meeting and one or more Board committee meetings, or two or more Board committee meetings, are held on the same date.

 

·                  Each Independent Trustee who serves as a committee chair of the Board’s Audit Committee, Compensation Committee or Nominating and Governance Committee receives an additional annual fee of $15,000, $10,000 and $10,000, respectively.

 

·                  Each Trustee receives a grant of 3,000 of the Company’s common shares of beneficial interest on the date of the first Board meeting following each annual meeting of shareholders (or, for Trustees who are first elected or appointed at other times, on the day of the first Board meeting attended).

 

·                  The Company generally reimburses all Trustees for travel expenses incurred in connection with their duties as Trustees and for out of pocket costs incurred in connection with their attending certain continuing education programs.Exhibit

EXHIBIT 10.1

AMENDMENT NO. 3
to the
2011 STOCK INCENTIVE PLAN
of
ASHFORD HOSPITALITY TRUST, INC.
May 16, 2017
This Amendment No. 3 (this “Amendment”) to the 2011 Stock Incentive Plan of Ashford Hospitality Trust, Inc. (the “Company”) is hereby adopted by the Board of Directors of the Company (the “Board”), effective as of the date first referenced above.
WHEREAS, the 2011 Stock Incentive Plan of Ashford Hospitality Trust, Inc. (the “Original Plan”) was authorized and approved by the stockholders of the Company and adopted for and on behalf of the Company by the Board in May 2011; and
WHEREAS, the Original Plan was amended by Amendment No. 1 which was authorized and approved by the stockholders of the Company at the Annual Meeting of Stockholders (as so amended, the “Amended Plan”); and 
WHEREAS, the Amended Plan was amended by Amendment No. 2 was adopted for and on behalf of the Company by the Board on August 2, 2016 (as so amended, the “Plan”); and
WHEREAS, pursuant to Article 1.4 of the Plan, any “material revision” of the Plan (as that term is used in the rules of the New York Stock Exchange) is subject to stockholder approval; and 
WHEREAS, the Board proposed and recommended that stockholders approve an amendment to the Plan authorizing an increase in the number of shares of Common Stock, $.01 par value per share, of the Company (“Common Stock”) that may be issued under the Plan by 5,750,000, and at the Annual Meeting of Stockholders held May 16, 2017, the stockholders approved such amendment by the affirmative vote of a majority of the votes cast at the annual meeting. 

NOW, THEREFORE, BE IT RESOLVED,
1.Article 1.2 of the Plan is hereby amended and restated in its entirety to read as follows:
1.2 Shares Subject to the Plan. The aggregate number of shares of Common Stock, $.01 par value per share, of the Company (“Common Stock”) that may be issued under the Plan commencing on May 13, 2014, the date the stockholders approved the amendment to the Plan set forth herein, shall not exceed 17,250,000 shares of outstanding Common Stock. The number of shares of Common Stock remaining available for issuance under the Plan, as of the date hereof, is 3,841,129, which amount was determined as follows:
	
			
	Total shares approved as of May 17, 2011
	5,750,000
	

	Shares granted pursuant to the Plan (net of shares returned to the Plan through forfeitures)
	(5,572,470
	)

	Additional shares approved May 13, 2014
	5,750,000
	

	Shares granted or reserved for issuance pursuant to the Plan (net of shares returned to the Plan through forfeitures)
	(4,727,383
	)

	Additional shares approved May 16, 2017
	5,750,000
	

	Shares granted or reserved for issuance pursuant to the Plan contingent upon approval of the Amendment
	(3,109,018
	)

	Total shares available under the Plan as of May 16, 2017
	3,841,129
	

In the event that at any time after the Effective Date the outstanding shares of Common Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a merger, consolidation, recapitalization, reclassification, stock split, stock dividend, combination of shares or the like, the aggregate number and class of securities available under the Plan shall be ratably adjusted by the Committee (as defined below), whose determination shall be final and binding upon the Company and all other interested persons. In the event the number of shares to be delivered upon the exercise or payment of any Award granted under the Plan is reduced for any reason whatsoever or in the event any Award granted under the Plan can no longer under any circumstances be exercised or paid, the number of shares no longer subject to such Award shall thereupon be released from such Award and shall thereafter be available under the Plan for the grant of additional Awards. Shares issued pursuant to the Plan (i) may be treasury shares, authorized but unissued shares or, if applicable, shares acquired in the open market and (ii) shall be fully paid and nonassessable.
2.Except as modified herein, all terms and conditions of the Plan shall remain in full force and effect.
3.This Amendment shall be construed and enforced in accordance with and governed by the laws of the State of Maryland, without regard to conflicts of law.
4.If any provision of this Amendment is or becomes invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.Exhibit 10.1

 

OPHTHALIX,
INC.

 STOCK
PURCHASE AGREEMENT

 

This
STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of _______________, 2017 by and between OphthaliX, Inc.,
a Delaware corporation (the “Company”) and Can-Fite Biopharma Ltd. (“Can-Fite”).

 

Background

 

A.       The
Company currently holds an aggregate of 1,000 ordinary shares, par value NIS 0.01 per share (the “EyeFite Common Stock”),
of EyeFite Ltd. (“EyeFite”) and the Company is the sole holder of all issued and outstanding shares
of the EyeFite Common Stock.

 

B.       The Company (including EyeFite) owes Can-Fite as of the date hereof, an aggregate amount
of US$[________] (including interest) under certain support letters issued by Can-Fite to the Company and attached herein as Exhibit
A (the “Deferred Debt”).

 

C.       The
Company and Can-Fite have agreed that as consideration for the purchase by Can-Fite of the shares of EyeFite Common Stock (the
“Shares”), Can-Fite shall irrevocably cancel and waive all indebtedness owed by the Company (including
any of its subsidiaries) to Can-Fite including, without limitation, the Deferred Debt (the “Indebtedness”).

 

D.       CanFite,
which is currently, and at Closing shall be, the owner, beneficially and of record, of approximately 82% of the outstanding shares
of the Company, acknowledges that it is buying the Shares on an “AS IS” basis and without the benefit of any representations
or warranties, express or implied, of any kind from the Company, EyeFite or any other person regarding the Shares or the assets,
liabilities or operations of EyeFite or otherwise, except as expressly set forth herein.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations, warranties and covenants hereinafter
set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereby agree as follows:

 

1.       
Sale of Shares.

 

1.1        Sale
of the Shares; Closing. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), Can-Fite
shall purchase the Shares, and the Company shall sell the Shares to Can-Fite, in consideration of the irrevocable cancellation
and waiver of the Indebtedness. The purchase and sale of the Shares and the cancellation and waiver of the Indebtedness shall
take place remotely via the exchange of documents and signatures on the date hereof, or at such other time and place as the Company
and Can-Fite mutually agree upon, orally or in writing (which time and place are designated as the “Closing”).

 

    	 	1	 

     

    

 

1.2        Delivery;
Payment. At the Closing, subject to the terms and conditions hereof, (a) Can-fite will deliver to the Company a certificate
representing the irrevocable cancellation and waiver of the Indebtedness, in the form attached hereto as Exhibit A (the
"Waiver") in exchange for (b) a signed and executed share transfer deed evidencing the transfer of the
Shares to Can-fite together with a share certificate representing the Shares.

 

2.       
Representations
and Warranties of the Company. The Company hereby represents and warrants to Can-Fite that, as of the date hereof and as of
the Closing:

 

2.1        Authorization.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement and the performance of all obligations of the Company hereunder, including the sale and delivery
of the Shares has been taken or will be taken prior to the Closing. This Agreement constitutes valid and legally binding obligations
of the Company, enforceable against the Company in accordance with its terms, except (a) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights
generally and (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.

 

2.2        Title
to the Shares. The Company has good and valid title to the Shares being transferred pursuant to this Agreement in consideration
for the cancellation and waiver of the Indebtedness and will deliver the Shares to Can-Fite free and clear of any security interests,
liens, claims or encumbrances.

 

2.3        No Other Representations. Except for the representations and warranties expressly and specifically made by the Company
in this Section 2, neither the Company nor any other person makes any other representation or warranty, whether expressed or implied,
and any reliance on part of CanFite and/or any of its Representatives on any such other representation or warranty is hereby expressly
disclaimed.

 

3.       
Representations
and Warranties of Can-Fite. Can-Fite hereby represents and warrants to the Company that, as of the date hereof and as of the
Closing:

 

3.1       Authorization.
Can-Fite has full power and authority to enter into this Agreement. All corporate action on the part of CanFite, its officers,
directors and stockholders necessary for the authorization, execution and delivery of this Agreement and the performance of all
obligations of CanFite hereunder, including the waiver of the Indebtedness has been taken or will be taken prior to the Closing.
This Agreement, when executed and delivered by Can-Fite, will constitute a valid and legally binding obligation of Can-Fite, enforceable
in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited
by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

3.2       No
Debt. Other than the Deferred Debt, which shall be irrevocably cancelled at the Closing, neither the Company nor any of its
subsidiaries (including EyeFite) owe (or following the Closing, will owe) CanFite, its officers or directors any funds.

  

    	 	2	 

     

    

 

3.3       
As-Is Transaction.

 

(a)        CanFite is experienced in the specific business of EyeFite and is aware of the risks involved in the industry in which EyeFite
is involved.

 

(b)        CanFite is acquiring the Shares pursuant to the terms of this Agreement for investment for its own account, not as a nominee or
agent.

 

(c)        CanFite acknowledges that it is accepting the Shares “AS IS.” CanFite has not relied on any representation, warranty
or statements, written or oral, other than the representations and warranties contained in Section 2 above, and, without derogating
from the generality of the foregoing, it has not received any guarantee, surety, undertaking or any other assurance, projection
or representation as to the future performance and/or business or other condition of EyeFite.

 

4.      
Conditions
to Closing.

 

4.1        Conditions
to the Obligation to Close. The parties' obligations to consummate the Closing shall be subject to the following:

 

(a)        The
Company’s delivery and surrender to Can-Fite of a share certificate representing the Shares (or in the case of a lost, stolen
or mutilated certificate, an affidavit of lost certificate).

 

(b)        The
Company executing a share transfer deed in favor of Can-Fite over the Shares, in the form attached hereto as Exhibit B.

 

(c)        The
Waiver duly signed and executed by Can-Fite.

 

5.       
Miscellaneous.

 

5.1        Survival
of Representations, Warranties and Covenants. The representations, warranties and covenants of the Company and Can-Fite contained
in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing.

 

5.2        Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

5.3        Governing
Law. This Agreement is to be construed in accordance with and governed by the internal laws of the State of Israel, without
giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal
laws of the State of Israel as to the rights and duties of the parties. The parties hereto irrevocably submit to the exclusive
jurisdiction of the courts in Tel-Aviv, Israel in respect of any dispute or matter arising out of or connected with this Agreement.

 

    	 	3	 

     

    

 

5.4        Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

5.5        Notices.
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement
shall be in writing and shall be deemed to have been duly given (a) when hand delivered to the other party; (b) the next business
day when sent by facsimile; or (c) the next business day after deposit with an international express delivery service (e.g., DHL
or Federal Express). All communications shall be sent to the address or facsimile of a party appearing in its signature block
hereto or at such address or facsimile as such party may designate.

 

5.6        Further
Assurances. Can-Fite and the Company shall from time to time and at all times hereafter make, do, execute, or cause or procure
to be made, done and executed such further acts, deeds, conveyances, consents and assurances without further consideration, which
may reasonably be required to effect the transactions contemplated by this Agreement.

 

5.7        Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties with respect
to the subject matter hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties
or covenants except as specifically set forth herein or therein. Any term of this Agreement may be amended and the observance
of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively),
only with the written consent of the Company and Can-Fite.

 

5.8        Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default
under this Agreement shall be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit,
consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver
on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law, or otherwise afforded
to any of the parties, shall be cumulative and not alternative.

 

5.9        Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable under applicable law, then
such provision shall be excluded from this Agreement and the remainder of this Agreement shall be interpreted as if such provision
were so excluded and shall be enforceable in accordance with its terms; provided, however, that in such event this Agreement
shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning
and intention of the excluded provision as determined by such court of competent jurisdiction.

 

5.10
     Headings. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

(Signature
Page Follows)

 

    	 	4	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Stock Purchase Agreement as of the date first written above.

 

 

	 	OPHTHALIX, INC.
	 	 	 
	 	By:	       
	 	Its:	 
	 	Title:	 
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 
	 	CAN-FITE BIOPHARMA LTD.
	 	 	 
	 	By:   	 
	 	Its:    	 
	 	Title:	 
	 	 	 
	 	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]